• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mcfarlane Neil F.

    10/10/23 8:20:58 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMPH alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    McFarlane Neil F.

    (Last) (First) (Middle)
    C/O ZEVRA THERAPEUTICS, INC.
    1180 CELEBRATION BOULEVARD, SUITE 103

    (Street)
    CELEBRATION FL 34747

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/10/2023
    3. Issuer Name and Ticker or Trading Symbol
    ZEVRA THERAPEUTICS, INC. [ ZVRA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit List: Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane 10/10/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KMPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMPH

    DatePrice TargetRatingAnalyst
    11/17/2022$20.00Overweight
    Cantor Fitzgerald
    9/15/2022$20.00Buy
    Canaccord Genuity
    1/31/2022$10.00 → $11.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $KMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on KemPharm with a new price target

    Cantor Fitzgerald initiated coverage of KemPharm with a rating of Overweight and set a new price target of $20.00

    11/17/22 7:28:54 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on KemPharm with a new price target

    Canaccord Genuity initiated coverage of KemPharm with a rating of Buy and set a new price target of $20.00

    9/15/22 7:21:45 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm upgraded by HC Wainwright & Co. with a new price target

    HC Wainwright & Co. upgraded KemPharm from Neutral to Buy and set a new price target of $11.00 from $10.00 previously

    1/31/22 7:18:55 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zevra Therapeutics Begins Trading as ZVRA

    Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwa

    3/1/23 7:43:50 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

    CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people. NORD is dedicated to promoting research and access to therapies for the more than 300 million people worldwide with rare disea

    2/28/23 8:00:00 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

    CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's 2023 Annual Meeting of Stockholders ("Annual Meeting"), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company's Annual Meeting — Richard W. Pascoe, David S. Tier

    2/27/23 4:30:03 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMPH
    SEC Filings

    View All

    SEC Form S-3 filed by KemPharm Inc.

    S-3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    2/2/24 9:39:30 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm Inc. filed SEC Form 8-K: Leadership Update

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    1/23/24 7:37:15 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    1/8/24 8:03:19 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schafer Joshua

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/2/24 9:22:49 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sangiovanni Timothy J.

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/2/24 8:17:46 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mickle Christal M M

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/2/24 8:14:52 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMPH
    Financials

    Live finance-specific insights

    View All

    Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

    CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.zevra.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on March 7, 2023. Additionally, in

    2/27/23 7:30:00 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm Reports Third Quarter 2022 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA resubmissionAdvancing key activities to initiate a Phase 2 clinical trial of KP1077 in IH by year-end 2022Total cash (cash, cash equivalents and long-term investments) of $107.4M as of Sep 30, 2022; based on current operating forecast, cash runway extends into 2026 CELEBRATION, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central ne

    11/9/22 4:05:00 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm to Report Third Quarter 2022 Financial Results

    CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022. The audio webcast with slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 6:

    11/1/22 7:30:00 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMPH
    Leadership Updates

    Live Leadership Updates

    View All

    KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

    Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial Officer and Executive Vice President of Business Development CELEBRATION, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced changes to its Board of Directors (Board) and executive leadership team as part of the Company's ongoing b

    1/9/23 6:30:00 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm Announces Appointment of Christopher Posner as New Independent Director

    24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

    11/29/22 7:30:00 AM ET
    $CARA
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

    CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications. In this newly created position, Ms. Ochsner will be responsible for driving external awareness of KemPharm's value proposition, including ongoing relations with the Company's shareholders, covering analysts and prospective investors. "We are very plea

    8/9/22 7:30:00 AM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by KemPharm Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    2/14/24 4:51:40 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KemPharm Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    1/29/24 5:25:49 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KemPharm Inc.

    SC 13G - KEMPHARM, INC (0001434647) (Subject)

    7/8/22 4:57:01 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care